CTLA4 and metastatic melanoma: A number of clinical case studies showed that concurrent treatment with radiotherapy and anti-CTLA-4 (ipilimumab) promoted an abscopal effect in metastatic melanoma (3 × 9.5 Gy) as well as in NSCLC (5 × 6 Gy in 10 days) (65, 66).